http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2384509-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4eb6dbca25e5f9459a6c5f592728c787 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2006-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c95eee310f4bb9332a8937bd69e8823c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc08765baa0ff6286a189e6b740c0529 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b41ccdec866c62ac5039d5ac7dc66e4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b38fa93e747444d960b12b872b878788 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2cea7883d8eea4bf5bf4bb192c05a061 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ff047044776cb77ba2523700b806615 |
| publicationDate | 2012-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2384509-T3 |
| titleOfInvention | Active heteroaryl pyrrolopyridinones as kinase inhibitors |
| abstract | A compound represented by the formula (I) in which A is selected from the group consisting of pyridin-4-yl, 3-fluoro-pyridin-4-yl, and 2-amino-pyrimidin-4-yl; R1 is selected from the group consisting of hydrogen, halogen and (C1-C6) alkyl; R2 is selected from the group consisting of hydrogen, (C1-C6) alkyl, (C1-C6) alkenyl, (C1-C6) alkynyl, (C3-C6) cycloalkyl, (C1-C6) haloalkyl, (C1-C6) alkyl ) polyfluorinated, heterocyclyl, aryl, heteroaryl, cycloalkyl (C3-C6) -alkyl (C1-C6), heterocyclyl-alkyl (C1-C6), aryl-alkyl (C1-C6), heteroaryl-alkyl (C1-C6), hydroxyalkyl (C1-C8), alkoxy (C1-C8) -alkyl (C1-C8), aryloxy-alkyl (C1-C8), heteroaryloxy-alkyl (C1-C8), aminoalkyl (C1-C8), alkylamino (C1- C8) - (C1-C8) alkyl, dialkylamino (C1-C8) -alkyl (C1-C8), carbamoyl-(C1-C8) alkyl, and alkoxycarbonyl, wherein each of said aryl, heteroaryl, heterocyclyl, aryloxy moieties, and heteroaryloxy may be unsubstituted or substituted with one or more substituents, each substituent being independently selected from the group consisting of alkyl, aryl, -OCF3, -OC (O) alkyl, -OC (O) aryl, -CF3, heteroaryl, aralkyl, alkylaryl, heteroaralkyl, alkylheteroaryl, hydroxy, hydroxyalkyl, alkoxy i, aryloxy, aralkoxy, acyl, aryl, halo, haloalkyl, haloalkoxy, nitro, cyano, carboxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylsulfinyl, arylsulfinyl, heteroarylsulfinyl, alkylthio, arylthio, heteroarylthio, aralkylthio, heteroaralkylthio, cycloalkyl, heterocyclyl, heterocyclynyl, - NH (alkyl), -NH (cycloalkyl), and -N (alkyl) 2; R3, R4, R5 and R6 are each independently selected from the group consisting of hydrogen, haloalkyl (C1-C6), alkyl (C1-C6) polyfluorinated, haloalkenyl (C1-C6), alkenyl (C1-C6) polyfluorinated, hydroxyalkyl (C1-C8), (C1-C8) alkoxy-(C1-C8) alkyl, aryloxy (C1-C8) alkyl, heteroaryloxy (C1-C8) alkyl, aryl (C1-C8) alkoxy-(C1-C8) alkyl -C8), azidoalkyl (C1-C8) group, aminoalkyl (C1-C8), alkylamino (C1-C8) -alkyl (C1-C8), dialkylamino (C1-C8) -alkyl (C1-C8), and alkyl ( C1-C8) -OC (O) -aminoalkyl (C1-C8), with the proviso that at least one of: R3, R4, R5 or R6 is different from hydrogen; or one of its pharmaceutically acceptable salts or solvates. |
| priorityDate | 2005-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 405.